Inclusion body myositis is a slowly progressive degenerative inflammatory disorder of skeletal muscles characterized by late onset weakness of specific muscle groups and distinctive histopathological features. Sporadic occurrence is the predominant inheritance pattern documented in this packet, though autosomal dominant transmission is also noted. Prevalence is estimated at 1–9 in 1,000,000, placing this condition among very rare diseases. Recognized subtypes documented in the packet include GNE myopathy and a form associated with proximal myopathy and ophthalmoplegia.

Six phenotypes are associated with inclusion body myositis in this packet, though individual phenotype details are not enumerated in the available source data. Clinical presentation is characterized by late onset weakness of specific muscle groups, as described in the disease definition, with adult onset documented among the onset categories in this packet.

The etiology of inclusion body myositis involves both sporadic and inherited mechanisms. Sporadic occurrence represents the predominant pattern, while autosomal dominant inheritance has also been documented in this packet. No specific gene associations are catalogued for this condition in the available source data. The disease definition characterizes the disorder as both degenerative and inflammatory in nature.

Specific diagnostic criteria for inclusion body myositis are not described in this packet. The disease definition references distinctive histopathological features as a component of characterization, alongside the pattern of late onset skeletal muscle weakness. Differentiation among recognized subtypes is an aspect of clinical evaluation given the spectrum encompassed by this disease category.

No FDA-approved therapeutic agents are recorded for inclusion body myositis in this packet. Four compounds have been subject to FDA orphan drug designation activity for this indication: arimoclomol (DESIGNATED), a humanized afucosylated IgG1 monoclonal antibody (DESIGNATED), an adeno-associated virus-delivered follistatin transgene (DESIGNATED), and bimagrumab (WITHDRAWN). Orphan drug designation does not constitute FDA approval for therapeutic use.

Specific natural history data and outcome information for inclusion body myositis are not available in this packet. The disease definition describes a slowly progressive course; this is the only prognosis-related characterization present in the source material reviewed.

Active clinical research programs are registered for inclusion body myositis, encompassing investigations of CAR T-cell therapies targeting CD19 and BCMA antigens, allogeneic cell therapy candidates, immunotherapy agents for autoimmune myopathy, functional biomarker monitoring studies, and multi-indication investigational programs. Studies span multiple phases and include both adult and juvenile myositis populations.